^®: CRE Regulatory Action of the Week

Information Quality Guidelines: EPA Ban on Third Party Clinical Human Test Data Violates Data Quality Act
CRE has informed EPA that the agency's ban on third party clinical human test data, pending National Academy of Sciences (NAS) review, violates the Data Quality Act. In its letter to EPA, the Center points out that these data are among the best available information regarding any substance's risk to human health, and the Act requires the agency to consider and use the best available data on health risks. Therefore, EPA's categorical refusal to consider these data is a clear violation of the Act and OMB's implementing Data Quality guidelines. CRE urges EPA to change its position now. CRE is including this letter as part of its comments on EPA's proposed Data Quality guidelines.